ibrutinib,acalabrutinib
astrazeneca,janssen,abbvie
['cll', 'acalabrutinib', 'ibru']
interesting post-hoc analysis of adverse events seen in phase 3 elevate-rr trial of acalabrutinib vs ibrutinib in patients with relapsed/refractory #cll presented in #asco22 which one do you use in your practice !
? #mediq22asco
Director-Heme Early Therapeutics & Leader-Leukemia/Myeloid Research @Yale. Personal views. I tweet on cancer, travel, food & soccer. COI: https://t.co/6XkF8CmtrK